No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Biotechnology
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
www.tigermedgrp.comNo one on the platform currently holds 3347.HK.
No tracked institution reports a position in 3347.HK as of their last filing.
No one on the platform has traded 3347.HK yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 4.0% | 10.1% | 13.8% | — | — | — |
| Rev. Growth % | 3.5% | 16.4% | ||||
| Profit Margin % | 13.0% | 26.0% | 26.5% | |||
| Free Cash Flow Margin % | 13.2% | 13.8% | 15.6% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $7.8B | +11.7% | $0.59 | $0.49–$0.64 | — | 5 |
| 2027 | $9.0B | +15.1% | $1.36 | $1.01–$1.70 | — | 5 |
| 2028 | $10.4B | +16.1% | $1.84 | $1.73–$1.93 | — | 2 |
| 2029 | $11.0B | +5.3% | $0.00 | $0.00–$0.00 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 1 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-28 | $0.25 | $-0.63 | -351.8% |
| 2026-04-28 | $0.27 | $0.07 | -74.9% |
| 2026-03-30 | $-0.08 | $-0.17 | -120.6% |
| 2025-10-28 | $0.35 | $0.81 | +134.1% |
| 2025-08-28 | $0.38 | $0.27 | -28.3% |
| 2025-04-28 | $0.39 | $0.20 | -48.6% |
| 2025-03-26 | $0.66 | $-0.50 | -176.3% |
| 2024-10-29 | $0.59 |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| 3347.HKHangzhou Tigermed Consulting Co., Ltd | $44.06 | +0.82% | $53.5B | — |
| 0874.HKGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $13.17 | -0.23% | $32.7B | — |
| 1099.HKSinopharm Group Co. Ltd. | $15.03 | -0.40% | $46.9B | — |
| 1877.HKShanghai Junshi Biosciences Co., Ltd. | $16.98 | -1.74% | $23.9B | — |
| 2228.HKXtalPi Holdings Ltd |
| $0.37 |
| -37.3% |
| $6.88 |
| -0.72% |
| $29.6B |
| — |
| 2268.HKWuXi XDC Cayman Inc | $74.85 | -0.40% | $94.8B | — |
| 2607.HKShanghai Pharmaceuticals Holding Co., Ltd | $10.86 | -1.36% | $63.0B | — |
Source: Financial Modeling Prep · peers by sector/industry